Cost-effectiveness analysis of oxaliplatin/5-fu/lv in adjuvant treatment of stage III colon cancer in the UK and Germany

被引：0
|
作者：
Aballea, S
Chancellor, J
Raikou, M
Drummond, M
Diel, R
Frick, M
Rosenfeld, S
Boler, A
Jourdan, S
Paulo, C
Bridgewater, J
机构：
[1] Innovus Res UK Ltd, High Wycombe, Bucks, England
[2] London Sch Econ, London, England
[3] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[4] Aventis Pharma Deutschland GmbH, Berlin, Germany
[5] Heron Evidence Dev, Letchworth Garden City, England
[6] Sanofi Aventis R&D, Bagneux, France
[7] UCL Royal Free & Univ Coll Med Sch, London, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67203-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A21 / A21
页数：1
相关论文
共 50 条
  • [21] Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer:: Preliminary analysis of the PETACC-2-study.
    Carrato, A.
    Köhne, C.
    Bedenne, L.
    Popov, I.
    Bouche, O.
    Gaspar, E.
    Rougier, P.
    Schubert, U.
    Biertz, F.
    Becker, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 161S - 161S
  • [22] Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer
    Soni, Amy
    Chu, Edward
    CLINICAL COLORECTAL CANCER, 2015, 14 (04) : 219 - 226
  • [23] Potential budget impact of capecitabine versus 5-FU/LV as adjuvant chemotherapy for stage III (SIII) colon cancer in Canada and its provinces
    Virik, K.
    Skedgel, C.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Adjuvant chemotherapy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis
    Bonistalli, L
    Bardelli, F
    Costantini, M
    Trallori, G
    d'Albasio, G
    Messori, A
    CANCER JOURNAL - FRANCE, 1998, 11 (01): : 39 - 47
  • [25] Efficacy of adjuvant chemotherapy with 5-FU/leucovorin and 5-FU/levamisole colon cancer
    Porschen, R
    Bermann, A
    Löffler, T
    Haack, G
    Rettig, K
    Anger, Y
    Strohmeyer, G
    GASTROENTEROLOGY, 1998, 114 (04) : A664 - A664
  • [26] ADJUVANT THERAPY FOR STAGE-III COLON-CANCER - ECONOMICS RETURNS TO RESEARCH AND COST-EFFECTIVENESS OF TREATMENT
    BROWN, ML
    NAYFIELD, SG
    SHIBLEY, LM
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) : 424 - 430
  • [27] Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 174 - 174
  • [28] Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, HJ
    Tabernero, J
    Nowacki, M
    Maroun, J
    Figer, A
    Price, T
    Lim, R
    van Cutsem, E
    Haller, D
    Braud, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [29] Capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    ANNALS OF ONCOLOGY, 2006, 17 : 25 - 26
  • [30] EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE
    Ducournau, P.
    Latimer, N.
    Sabate, E.
    Walzer, S.
    VALUE IN HEALTH, 2008, 11 (06) : A471 - A472
12345